マーケットレポート詳細
血友病治療薬の世界市場：2031年予測
Hemophilia Treatment Drugs Market (Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
- 出版元：Transparency Market Research
出版元について - 発行年：2023年11月
- 定価 ：Single User License(1名様ライセンス)US$5,795(米国ドル)/Multi User License(5名様)$8,795 /Enterprise License $11,705
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文188ページになります。
- 商品コード：TMR120
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
血友病治療薬の世界市場規模は2022年で118億ドル、2031年に186億ドル、市場の平均年成長率は5.0%になると予想されています。
当レポートでは、血友病治療薬の市場予測-2031年、各種セグメント別市場分析(製品別、疾患別、国地域別、等)、市場ダイナミクス、競合状況、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。
【レポート構成概要】
■血友病治療薬の世界市場予測2023-2031年
・市場規模(US$)
■製品別、市場-2031年
遺伝子組換え型血液凝固因子製剤
・第VIII因子製剤
・第IX因子製剤
・その他
血漿由来凝固因子製剤
・第VIII因子
・第IX因子
・その他
その他
※(市場規模US$)
■疾患別、市場-2031年
血友病A
血友病B
その他
※(市場規模US$)
■販売経路別、市場-2031年
病院薬局
小売薬局
オンライン薬局
※(市場規模US$)
■主要国地域別市場-2031年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
南米
・ブラジル、メキシコ
・その他南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照
■市場分析
市場ダイナミクス（促進要因、障壁、機会）
COVID-19の影響分析
競合状況
市場シェア分析
SWOT分析
■血友病治療薬の主要企業プロフィール動向
Pfizer Inc.
CSL Behring
Kedrion
武田薬品工業株式会社
Novo Nordisk A/S
Bayer AG
F. Hoffmann-La Roche Ltd.
Octapharma AG
Biotest AG
Sanofi S.A.
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Hemophilia Treatment Drugs Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hemophilia Treatment Drugs Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. List of Types of Hemophilia Treatment Drugs
5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
5.4. COVID-19 Pandemic Impact on Industry
6. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2023–2031
6.3.1. Recombinant Coagulation Factor Concentrates
6.3.1.1. Factor VIII
6.3.1.2. Factor IX
6.3.1.3. Others
6.3.2. Plasma-derived Coagulation Factor Concentrates
6.3.2.1. Factor VIII
6.3.2.2. Factor IX
6.3.2.3. Others
6.3.3. Others
6.4. Market Attractiveness, by Product
7. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2023–2031
7.3.1. Hemophilia A
7.3.2. Hemophilia B
7.3.3. Others
7.4. Market Attractiveness, by Disease Indication
8. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2023–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Hemophilia Treatment Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Hemophilia Treatment Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2023–2031
10.2.1. Recombinant Coagulation Factor Concentrates
10.2.1.1. Factor VIII
10.2.1.2. Factor IX
10.2.1.3. Others
10.2.2. Plasma-derived Coagulation Factor Concentrates
10.2.2.1. Factor VIII
10.2.2.2. Factor IX
10.2.2.3. Others
10.2.3. Others
10.3. Market Attractiveness, by Product
10.4. Market Value Forecast, by Disease Indication, 2023–2031
10.4.1. Hemophilia A
10.4.2. Hemophilia B
10.4.3. Others
10.5. Market Attractiveness, by Disease Indication
10.6. Market Value Forecast, by Distribution Channel, 2023–2031
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Online Pharmacies
10.7. Market Attractiveness, by Distribution Channel
10.8. Market Value Forecast, by Country, 2023–2031
10.8.1. U.S.
10.8.2. Canada
10.9. Market Attractiveness Analysis
10.9.1. By Product
10.9.2. By Disease Indication
10.9.3. By Distribution Channel
10.9.4. By Country
11. Europe Hemophilia Treatment Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Recombinant Coagulation Factor Concentrates
11.1.2.1. Factor VIII
11.1.2.2. Factor IX
11.1.2.3. Others
11.1.3. Plasma-derived Coagulation Factor Concentrates
11.1.3.1. Factor VIII
11.1.3.2. Factor IX
11.1.3.3. Others
11.1.4. Others
11.2. Market Attractiveness, by Product
11.3. Market Value Forecast, by Disease Indication, 2023–2031
11.3.1. Hemophilia A
11.3.2. Hemophilia B
11.3.3. Others
11.4. Market Attractiveness, by Disease Indication
11.5. Market Value Forecast, by Distribution Channel, 2023–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Attractiveness, by Distribution Channel
11.7. Market Value Forecast, by Country/Sub-region, 2023–2031
11.7.1. Germany
11.7.2. U.K.
11.7.3. France
11.7.4. Italy
11.7.5. Spain
11.7.6. Rest of Europe
11.8. Market Attractiveness Analysis
11.8.1. By Product
11.8.2. By Disease Indication
11.8.3. By Distribution Channel
11.8.4. By Country/Sub-region
12. Asia Pacific Hemophilia Treatment Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2023–2031
12.2.1. Recombinant Coagulation Factor Concentrates
12.2.1.1. Factor VIII
12.2.1.2. Factor IX
12.2.1.3. Others
12.2.2. Plasma-derived Coagulation Factor Concentrates
12.2.2.1. Factor VIII
12.2.2.2. Factor IX
12.2.2.3. Others
12.2.3. Others
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Disease Indication, 2023–2031
12.4.1. Hemophilia A
12.4.2. Hemophilia B
12.4.3. Others
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Distribution Channel, 2023–2031
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Attractiveness, by Distribution Channel
12.8. Market Value Forecast, by Country/Sub-region, 2023–2031
12.8.1. China
12.8.2. Japan
12.8.3. India
12.8.4. Australia & New Zealand
12.8.5. Rest of Asia Pacific
12.9. Market Attractiveness Analysis
12.9.1. By Product
12.9.2. By Disease Indication
12.9.3. By Distribution Channel
12.9.4. By Country/Sub-region
13. Latin America Hemophilia Treatment Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2023–2031
13.2.1. Recombinant Coagulation Factor Concentrates
13.2.1.1. Factor VIII
13.2.1.2. Factor IX
13.2.1.3. Others
13.2.2. Plasma-derived Coagulation Factor Concentrates
13.2.2.1. Factor VIII
13.2.2.2. Factor IX
13.2.2.3. Others
13.2.3. Others
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Disease Indication, 2023–2031
13.4.1. Hemophilia A
13.4.2. Hemophilia B
13.4.3. Others
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Distribution Channel, 2023–2031
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Attractiveness, by Distribution Channel
13.8. Market Value Forecast, by Country/Sub-region, 2023–2031
13.8.1. Brazil
13.8.2. Mexico
13.8.3. Rest of Latin America
13.9. Market Attractiveness Analysis
13.9.1. By Product
13.9.2. By Disease Indication
13.9.3. By Distribution Channel
13.9.4. By Country/Sub-region
14. Middle East & Africa Hemophilia Treatment Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2023–2031
14.2.1. Recombinant Coagulation Factor Concentrates
14.2.1.1. Factor VIII
14.2.1.2. Factor IX
14.2.1.3. Others
14.2.2. Plasma-derived Coagulation Factor Concentrates
14.2.2.1. Factor VIII
14.2.2.2. Factor IX
14.2.2.3. Others
14.2.3. Others
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Disease Indication, 2023–2031
14.4.1. Hemophilia A
14.4.2. Hemophilia B
14.4.3. Others
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Distribution Channel, 2023–2031
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Attractiveness, by Distribution Channel
14.8. Market Value Forecast, by Country/Sub-region, 2023–2031
14.8.1. GCC Countries
14.8.2. South Africa
14.8.3. Rest of Middle East & Africa
14.9. Market Attractiveness Analysis
14.9.1. By Product
14.9.2. By Disease Indication
14.9.3. By Distribution Channel
14.9.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Pfizer Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. CSL Behring
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Kedrion
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Takeda Pharmaceutical Company Limited
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Novo Nordisk A/S
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Bayer AG
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Octapharma AG
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Biotest AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Sanofi S.A.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
List of Tables
Table 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031
Table 2: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031
Table 3: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 4: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Region, 2023–2031
Table 5: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country, 2023–2031
Table 6: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031
Table 7: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031
Table 8: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 9: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031
Table 11: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031
Table 12: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031
Table 13: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031
Table 15: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031
Table 16: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel, 2023–2031
Table 17: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 18: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031
Table 19: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031
Table 20: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031
Table 21: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Country/Sub-region, 2023–2031
Table 22: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Product, 2023–2031
Table 23: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Disease Indication, 2023–2031
Table 24: Middle East & Africa Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, by Distribution Channel 2023–2031
List of Figures
Figure 1: Global Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 2: Global Hemophilia Treatment Drugs Market Value Share, by Product, 2022
Figure 3: Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2022
Figure 4: Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2022
Figure 5: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 6: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031
Figure 7: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 8: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031
Figure 9: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 10: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 11: Global Hemophilia Treatment Drugs Market Value Share Analysis, by Region, 2022 and 2031
Figure 12: Global Hemophilia Treatment Drugs Market Attractiveness Analysis, by Region, 2023–2031
Figure 13: North America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 14: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Country, 2022 and 2031
Figure 15: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 16: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 17: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031
Figure 18: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 19: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031
Figure 20: North America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 21: North America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 22: Europe Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 23: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 24: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 25: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 26: Europe America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031
Figure 27: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 28: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031
Figure 29: Europe Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 30: Europe Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 31: Asia Pacific Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 32: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 34: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 35: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031
Figure 36: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 37: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031
Figure 38: Asia Pacific Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 39: Asia Pacific Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 40: Latin America Hemophilia Treatment Drugs Market Value (US$ Bn) Forecast, 2023–2031
Figure 41: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 43: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2022 and 2031
Figure 44: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031
Figure 45: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Disease Indication, 2022 and 2031
Figure 46: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Disease Indication, 2023–2031
Figure 47: Latin America Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 48: Latin America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 49: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 50: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 51: Middle East & Africa America Hemophilia Treatment Drugs Market Value Share Analysis, by Product, 2023–2031
Figure 52: Middle East & Africa America Hemophilia Treatment Drugs Market Attractiveness Analysis, by Product, 2023–2031
Figure 53: Middle East & Africa Hemophilia Treatment Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 54: Middle East & Africa Hemophilia Treatment Drugs Market Attractiveness Analysis, by Distribution Channel 2023–2031
Figure 55: Global Hemophilia Treatment Drugs Market Share Analysis, by Company (2022)